BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 31235408)

  • 41. Resin Versus Glass Microspheres for
    Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N
    J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
    Aoyagi Y; Oguro M; Yanagi M; Mita Y; Suda T; Suzuki Y; Hata K; Ichii K; Asakura H
    Cancer; 1996 May; 77(9):1781-6. PubMed ID: 8646674
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein alone and those seropositive for des-gamma-carboxy prothrombin alone.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M
    J Gastroenterol Hepatol; 2001 Nov; 16(11):1290-6. PubMed ID: 11903749
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma.
    Nakao A; Taniguchi K; Inoue S; Harada A; Nonami T; Watanabe K; Takagi H
    Semin Surg Oncol; 1996; 12(3):160-3. PubMed ID: 8727604
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin.
    Grazi GL; Mazziotti A; Legnani C; Jovine E; Miniero R; Gallucci A; Palareti G; Gozzetti G
    Liver Transpl Surg; 1995 Jul; 1(4):249-55. PubMed ID: 9346575
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern.
    Gao F; Zhu HK; Zhu YB; Shan QN; Ling Q; Wei XY; Xie HY; Zhou L; Xu X; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2016 Aug; 15(4):371-7. PubMed ID: 27498576
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
    Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Toxicity and Survival of Hepatocellular Carcinoma Patients with Hepatitis B Infection Treated with Yttrium-90 Radioembolization: An Updated 15-Year Study.
    Gao R; Gabr A; Mouli S; Riaz A; Kulik L; Lewandowski RJ; Salem R
    J Vasc Interv Radiol; 2020 Mar; 31(3):401-408.e1. PubMed ID: 31983593
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization.
    Hardy-Abeloos C; Lazarev S; Ru M; Kim E; Fischman A; Moshier E; Rosenzweig K; Buckstein M
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):968-976. PubMed ID: 31536781
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States.
    Carr BI; Kanke F; Wise M; Satomura S
    Dig Dis Sci; 2007 Mar; 52(3):776-82. PubMed ID: 17253135
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Nakazawa T; Hidaka H; Takada J; Okuwaki Y; Tanaka Y; Watanabe M; Shibuya A; Minamino T; Kokubu S; Koizumi W
    Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):683-9. PubMed ID: 23395995
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnostic Value of Serum Biomarkers for Patients Undergoing Curative Resection with Non-B, Non-C Hepatocellular Carcinoma.
    Li Y; Chen Y; Chen J
    J Coll Physicians Surg Pak; 2020 Feb; 30(2):134-138. PubMed ID: 32036818
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early-Stage Hepatocellular Carcinoma.
    Choi J; Kim GA; Han S; Lee W; Chun S; Lim YS
    Hepatology; 2019 May; 69(5):1983-1994. PubMed ID: 30153338
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma.
    Shindoh J; Sugawara Y; Nagata R; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Tanaka T; Kokudo N
    Transpl Int; 2014 Apr; 27(4):391-8. PubMed ID: 24472068
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnostic utility of alpha-fetoprotein and des-gamma-carboxyprothrombin in nigerians with hepatocellular carcinoma.
    Ette AI; Ndububa DA; Adekanle O; Ekrikpo U
    Niger J Clin Pract; 2017 Oct; 20(10):1267-1272. PubMed ID: 29192630
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum Des-gamma-carboxy Prothrombin for Diagnosis of Adult Primary Cancer in Liver.
    Li Y; Chen J
    J Coll Physicians Surg Pak; 2019 Oct; 29(10):972-976. PubMed ID: 31564273
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma.
    Inoue S; Nakao A; Harada A; Nonami T; Takagi H
    Am J Gastroenterol; 1994 Dec; 89(12):2222-6. PubMed ID: 7526679
    [TBL] [Abstract][Full Text] [Related]  

  • 58. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC.
    Yamamoto K; Imamura H; Matsuyama Y; Kume Y; Ikeda H; Norman GL; Shums Z; Aoki T; Hasegawa K; Beck Y; Sugawara Y; Kokudo N
    J Gastroenterol; 2010 Dec; 45(12):1272-82. PubMed ID: 20625772
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C.
    Sterling RK; Wright EC; Morgan TR; Seeff LB; Hoefs JC; Di Bisceglie AM; Dienstag JL; Lok AS
    Am J Gastroenterol; 2012 Jan; 107(1):64-74. PubMed ID: 21931376
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma.
    Sassa T; Kumada T; Nakano S; Uematsu T
    Eur J Gastroenterol Hepatol; 1999 Dec; 11(12):1387-92. PubMed ID: 10654799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.